X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Expected to Post FY2026 Earnings of $0.32 Per Share

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Equities research analysts at Brookline Capital Management raised their FY2026 earnings estimates for shares of X4 Pharmaceuticals in a research report issued on Monday, April 29th. Brookline Capital Management analyst L. Cann now forecasts that the company will earn $0.32 per share for the year, up from their prior forecast of $0.30. The consensus estimate for X4 Pharmaceuticals' current full-year earnings is ($0.47) per share. Brookline Capital Management also issued estimates for X4 Pharmaceuticals' FY2027 earnings at $0.85 EPS.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last released its quarterly earnings data on Thursday, March 21st. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.05.

Separately, HC Wainwright increased their price target on shares of X4 Pharmaceuticals from $3.00 to $5.00 and gave the stock a "buy" rating in a research note on Tuesday.

X4 Pharmaceuticals Price Performance

Shares of XFOR stock traded down $0.02 on Wednesday, reaching $1.11. The company's stock had a trading volume of 3,514,611 shares, compared to its average volume of 2,594,845. The stock's 50 day simple moving average is $1.15 and its 200-day simple moving average is $0.93. The company has a market capitalization of $185.57 million, a P/E ratio of -1.82 and a beta of 0.49. X4 Pharmaceuticals has a 12-month low of $0.57 and a 12-month high of $2.58. The company has a quick ratio of 5.34, a current ratio of 5.34 and a debt-to-equity ratio of 1.07.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several institutional investors have recently bought and sold shares of XFOR. SG Americas Securities LLC boosted its position in shares of X4 Pharmaceuticals by 38.8% during the 4th quarter. SG Americas Securities LLC now owns 47,668 shares of the company's stock valued at $40,000 after purchasing an additional 13,328 shares in the last quarter. Barclays PLC lifted its position in X4 Pharmaceuticals by 334.8% during the 3rd quarter. Barclays PLC now owns 382,134 shares of the company's stock worth $417,000 after acquiring an additional 294,255 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of X4 Pharmaceuticals during the 3rd quarter worth about $678,000. Stonepine Capital Management LLC boosted its position in shares of X4 Pharmaceuticals by 14.5% during the 3rd quarter. Stonepine Capital Management LLC now owns 5,273,685 shares of the company's stock valued at $5,748,000 after acquiring an additional 668,422 shares in the last quarter. Finally, Bain Capital Life Sciences Investors LLC raised its holdings in shares of X4 Pharmaceuticals by 6.0% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 16,915,784 shares of the company's stock worth $14,184,000 after buying an additional 955,196 shares in the last quarter. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at X4 Pharmaceuticals

In other news, CFO Adam S. Mostafa sold 27,721 shares of the business's stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $1.01, for a total value of $27,998.21. Following the completion of the sale, the chief financial officer now directly owns 52,500 shares in the company, valued at $53,025. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Paula Ragan sold 49,678 shares of the business's stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $0.88, for a total transaction of $43,716.64. Following the transaction, the chief executive officer now directly owns 765,068 shares in the company, valued at $673,259.84. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Adam S. Mostafa sold 27,721 shares of the firm's stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $1.01, for a total transaction of $27,998.21. Following the transaction, the chief financial officer now owns 52,500 shares of the company's stock, valued at $53,025. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 185,708 shares of company stock valued at $170,428. 1.08% of the stock is currently owned by corporate insiders.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.